NCT04326218 Immunopathological Analysis in a French National Cohort of Membranous Nephropathy
| NCT ID | NCT04326218 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Nice |
| Condition | Membranous Nephropathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2020-07-04 |
| Primary Completion | 2031-06-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2020-07-04 with a primary completion date of 2031-06-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
National cohort of all cases of membranous nephropathy (MN) during a 1 year period in France, based on a pathological and/or serological diagnostic, collecting the data on: * incidence of MN * prevalence of anti-PLA2R1 and anti-THSD7A * clinical outcome one year after diagnosis or after relapse (complete remission, partial remission or persistent nephrotic syndrome) * environmental risk factors for the onset of MN * HLA markers * patient care status in France
Eligibility Criteria
Inclusion Criteria: * Age 18 years or more * Biopsy on a native kidney consistent with MN and/or positivity for serum anti-PLA2R1 and/or anti-THSD7A antibodies * Signed informed consent Exclusion Criteria: * Diagnosis error based on the kidney biopsy staining or on serology analyses for the positivity for anti-PLA2R1 and/or anti-THSD7A * Patients unable to give an informed consent * Patients withdrawing an informed consent
Contact & Investigator
Barbara Seitz-polski
PRINCIPAL INVESTIGATOR
Hopital de l'Archet laboratoire immunology, 151 route de sain-Antoine de Ginestière 06200 Nice
Frequently Asked Questions
Who can join the NCT04326218 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Membranous Nephropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04326218 currently recruiting?
Yes, NCT04326218 is actively recruiting participants. Contact the research team at seitz-polski.b@chu-nice.fr for enrollment information.
Where is the NCT04326218 trial being conducted?
This trial is being conducted at Nice, France.
Who is sponsoring the NCT04326218 clinical trial?
NCT04326218 is sponsored by Centre Hospitalier Universitaire de Nice. The principal investigator is Barbara Seitz-polski at Hopital de l'Archet laboratoire immunology, 151 route de sain-Antoine de Ginestière 06200 Nice. The trial plans to enroll 400 participants.